• Eli Lilly reported sustained benefits from combining Taltz with Zepbound over one year in its Phase 3b TOGETHER-PsA trial.
• The combination improved disease control versus Taltz alone in adults with psoriatic arthritis and obesity or overweight with weight-related conditions.
• Physical function, fatigue and metabolic health also improved versus Taltz alone; adverse events were generally mild to moderate.
• The findings were presented at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611110945PR_NEWS_USPR_____DE94223) on November 11, 2026, and is solely responsible for the information contained therein.